RNA sequencing on iPSC-derived iSOX9-astrocytes

We generated a stable healthy and diseased (with ALS-linked FUS-R521H mutation) iPSC line containing the coding sequence of SOX9 under a Tet-on promotor in the safe harbor AAVS1 locus via recombinase-mediated cassette exchange. This allows the induction of SOX9 expression after doxycycline addition and generates in this way PSC-derived astrocytes. RNASeq is performed on these healthy and diseased iSOX9-astrocytes at an early and late timepoint. In addition, we included commercially available PSC-derived astrocytes (called "iCell") and fetal human primary astrocytes (called "fHA"). Overall design: Expression characterisation of iSOX9-astrocytes: we included early and late iSOX9 astrocytes generated from healthy and diseased iPSCs. In addition, iCell and fHA cells were included. All samples were sequenced in triplicate (3 independent differentiation for the iSOX9-astrocytes).